ShanghaiMay 8, 2026 /PRNewswire/ — On May 7, 2026, ahead of World Ovarian Cancer Day, a public welfare event themed “We Stand by You” warmly kicked off in Shanghai. Organized by the Gynecological Oncology Committee of the Shanghai Anti-Cancer Association and supported by Hengrui Oncology, the event focused on ovarian cancer prevention education and women’s health protection. Through gentle musical healing and moving life-image exhibitions, it conveyed strength via science and ignited hope through stories. Medical experts, patient representatives, and caring enterprises gathered to hold up a health umbrella for every woman, accompanying them with love and courage.
Using Music and Images to Make “Seeing” the Beginning of Protection
The entire event was structured around three movements: “Healing Her • Resonance,” “Healing Her • Hope,” and “Healing Her • Rebirth,” using melodies to express the emotional journey of ovarian cancer patients from confusion and struggle to newfound life. At the event, medical experts delivered scientific explanations, patient representatives shared real stories, and multidisciplinary teams engaged in cross-sector Q&A sessions, weaving together professionalism and warmth, and serving as a bridge to transmit strength and faith. Every participant could truly feel the warmth of “We Stand by You” through the notes.
We Stand by You – World Ovarian Cancer Care Day Public Welfare Event
Professor Wang Yu from Shanghai Shenkang Hospital Development Center, Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, Professor Yao Liangqing from Obstetrics and Gynecology Hospital of Fudan University, Professor Liu Kaijiang from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor Cheng Jingxin from Shanghai East Hospital Affiliated to Tongji University, Professor Xu Mingjuan from Shanghai Changhai Hospital, Professor Feng Zheng from Fudan University Shanghai Cancer Center, along with Mr. Zhu Guoxin, Senior Vice President and Head of Global Early Development at Hengrui Medicine, and Mr. Peng Pai, Deputy General Manager of the Oncology Division, jointly attended the event.
Ms. Liu (a pseudonym), an ovarian cancer patient, said: “On the road to fighting ovarian cancer, we often fall into confusion and helplessness. Today, coming to the ‘We Stand by You’ public welfare event, seeing experts, doctors, caring enterprises, and many strangers conveying support and care for us, I deeply feel that I am not alone. If medical advances bring us hope, then the love from doctors and society gives us the courage to fight the disease, allowing us to move forward with a more determined and positive mindset.”
Understanding the Truth of the Disease: Using Scientific Strength to Counter the Threat of Ovarian Cancer
Ovarian cancer is widely recognized as the “king of gynecological cancers” and is one of the most severe gynecological malignancies threatening women’s lives and health. Due to its insidious onset, difficulty in early diagnosis, high recurrence rate, and poor prognosis, it has long ranked first in mortality among gynecological tumors. Because the ovaries are deeply located in the pelvic cavity, early-stage lesions often show no typical symptoms, leading to about 70% of patients being diagnosed at an advanced stage[1], missing the optimal treatment window.
In China, there are approximately 61,000 new cases of ovarian cancer each year, with the incidence rate slowly rising[2]. The onset of ovarian cancer is associated with multiple factors, including genetics, reproductive and endocrine levels, environment, and lifestyle. Early-stage ovarian cancer often presents with signals such as abdominal bloating, pain, increased abdominal girth, frequent urination, constipation, and abnormal fatigue or weight loss.
Traditional treatment for ovarian cancer primarily involves cytoreductive surgery combined with platinum-based chemotherapy. While this can control the disease during initial treatment, it struggles to prevent repeated recurrences. Clinical data show that nearly 70% of patients experience recurrence within two years of treatment[3], and as the number of recurrences increases, chemotherapy sensitivity decreases, leading to increasingly limited treatment options. Currently, the five-year survival rate for advanced ovarian cancer patients in China remains below 30%, with the disease burden continuing to escalate[4].
Notably, in recent years, with the advent of innovative targeted therapies such as PARP inhibitors and the promotion of standardized treatment, the landscape of ovarian cancer treatment has seen significant breakthroughs, offering new hope for delaying recurrence, extending survival, and improving quality of life. Professor Wu Xiaohua from Fudan University Shanghai Cancer Center stated: “Currently, with the continuous advancement of surgical techniques, the ongoing innovation of targeted therapies, and the gradual improvement of multidisciplinary standardized treatment systems, the comprehensive treatment level for ovarian cancer has significantly improved. More and more ovarian cancer patients are expected to achieve longer survival times and better quality of life. At the same time, as physicians, we not only need to treat the disease but also ensure patients feel understood and accompanied. This ‘We Stand by You’ public welfare event aims to pass on this hope and care to more people—helping the public understand ovarian cancer and value early screening, while also enabling more patients to truly feel: they are not alone, and we are always here to protect them.”
Innovation Leading Development: Building a Comprehensive Care and Support System
Rooted in strong independent R&D capabilities, Hengrui continues to push the boundaries of women’s cancer treatment, achieving a leap from Chinese “intelligent” manufacturing to Chinese solutions, and from single-product innovation to the construction of a full-cycle treatment ecosystem. Currently, within Hengrui’s women’s cancer product portfolio, multiple products such as Aiyirui®, Aibite®, Airuini®, Airuikang®, and Aiweida® have formed a powerful synergistic effect, truly realizing a “Chinese treatment plan” covering core tumor types such as ovarian cancer, cervical cancer, and breast cancer, spanning the entire disease course. At the same time, Hengrui Oncology remains committed to its “Heng Ai” (Eternal Love)初心, continuously striving to improve patients’ quality of life, from enhancing drug accessibility to full-cycle patient care, empowering women’s cancer patients across all dimensions.
Care extends beyond a single day; protection is always online. In the future, Hengrui Oncology will continue to be patient-centered, intensifying innovative R&D in anti-tumor drugs, safeguarding national health with more high-quality, independently innovative drugs, while extensively rallying forces from all sectors of society to jointly advance public health welfare initiatives further and deeper.
About Hengrui Oncology
Hengrui Oncology is one of the core strategic business segments of Hengrui Medicine, focusing on the R&D, production, and global expansion of innovative oncology drugs. Hengrui has built a “four-in-one” synergistic innovative therapy system in the oncology field, forming a complete ecosystem covering precision therapy, immunotherapy, targeted chemotherapy, and supportive care, emphasizing both extending patient survival and improving quality of life. On this basis, it has further developed a “multi-mechanism synergy, full-cycle coverage” oncology product matrix, creating a systematic layout covering seven major disease areas, oncology supportive care, and multiple significant unmet clinical needs. Currently, Hengrui Oncology has 16 self-developed innovative drugs on the market, with nearly 60 independently developed innovative drug candidates in the pipeline, conducting over 150 clinical trials for major R&D pipelines globally. Multiple products have received U.S. Orphan Drug and Fast Track designations. In the future, Hengrui Oncology will continue to be driven by source innovation, building a globally competitive innovative product system.